Drug eluting stent implantation for in-stent restenosis: angiographic results of the principal studies
| TAXUS-III16 | FIM-Rotterdam12 | FIM-São Paulo13 | ISR post-brachytherapy24 | RESEARCH registry | ||
|---|---|---|---|---|---|---|
| *In-stent plus 5 mm segment proximal and distal to the stent; †in-stent only. | ||||||
| ISR, in-stent restenosis; LVEF, left ventricular ejection fraction; RESEARCH, rapamycin eluting stent evaluated at Rotterdam cardiology hospital. | ||||||
| Drug | Paclitaxel | Sirolimus | Sirolimus | Sirolimus | Sirolimus | |
| Patients | 28 | 16 | 25 | 12 | 44 | |
| Inclusion criteria | Single lesion, native coronary artery; vessel size 3.0–3.5 mm | Single lesion; native coronary artery; vessel size 2.5–3.5 mm | Single lesion; native coronary artery; vessel size 2.5–3.5 mm | Previous brachytherapy | All clinical and anatomical conditions | |
| Exclusion criteria | Acute myocardial infarction; lesion length >30 mm; total occlusion; LVEF <30%; renal dysfunction | Saphenous vein graft | Previous brachytherapy; lesion length >36 mm; total occlusion | NA | Previous brachytherapy | |
| Reference diameter (mm) | 2.75 (1.20) | 2.68 (0.33) | 2.78 (0.30) | 2.83 (0.48) | 2.64 (0.56) | |
| Lesion length (mm) | 13.6 (6.4) | 18.4 (13.1) | 13.6 (7.65) | NA | 17.5 (12.1) | |
| Stent length (mm) | 22 (8) | 28 (18) | 22 (7) | 34 (30) | 28 (20) | |
| Time of follow up (months) | 6 | 6 | 4 | 12 | 6 | 6 |
| Late loss (mm)* | 0.54 (0.51)† | 0.26 (0.67) | −0.05 (0.30) | 0.16 (0.42) | 0.68 (1.2) | 0.17 (0.760 |
| Binary restenosis* | 16.0% | 20.0% | 0% | 4.0% | 40.0% | 14.6% |